Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Hills Bank & Trust Co

Hills Bank & Trust Co lowered its stake in Illumina, Inc. (NASDAQ:ILMN) by 16.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 4,313 shares of the life sciences company’s stock after selling 855 shares during the quarter. Hills Bank & Trust Co’s holdings in Illumina were worth $601,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Illumina during the third quarter worth about $30,000. VisionPoint Advisory Group LLC grew its position in Illumina by 344.6% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 193 shares during the last quarter. Wetzel Investment Advisors Inc. acquired a new stake in shares of Illumina during the fourth quarter worth about $37,000. Gradient Investments LLC grew its holdings in shares of Illumina by 375.0% during the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock worth $40,000 after buying an additional 225 shares during the last quarter. Finally, North Star Investment Management Corp. increased its position in Illumina by 183.0% in the 4th quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock valued at $42,000 after acquiring an additional 194 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 0.7 %

ILMN traded up $0.73 during midday trading on Thursday, hitting $111.35. The company’s stock had a trading volume of 1,755,039 shares, compared to its average volume of 1,740,209. The firm has a market cap of $17.74 billion, a P/E ratio of -13.66 and a beta of 1.20. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $213.91. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. The firm has a 50-day moving average price of $128.53 and a two-hundred day moving average price of $126.83.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.04 by $0.05. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. Illumina’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.08 earnings per share. On average, research analysts anticipate that Illumina, Inc. will post 0.91 earnings per share for the current year.

Insider Activity at Illumina

In other news, CEO Jacob Thaysen bought 7,330 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was acquired at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the acquisition, the chief executive officer now owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.17% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on ILMN shares. OTR Global reiterated a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Royal Bank of Canada reiterated an “outperform” rating and set a $253.00 price target on shares of Illumina in a research note on Tuesday, April 9th. Robert W. Baird raised their price objective on shares of Illumina from $125.00 to $128.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. HSBC lowered Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. Finally, Barclays lifted their price target on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research report on Wednesday, April 10th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Illumina has an average rating of “Hold” and an average target price of $164.65.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.